{"id":391200,"date":"2015-12-17T00:00:00","date_gmt":"2015-12-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nmrdid0415-biopharma-hemophilia-niche-and-rare-pharmacor-g7-2015\/"},"modified":"2026-04-14T10:28:25","modified_gmt":"2026-04-14T10:28:25","slug":"nmrdid0415-biopharma-hemophilia-niche-and-rare-pharmacor-g7-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nmrdid0415-biopharma-hemophilia-niche-and-rare-pharmacor-g7-2015\/","title":{"rendered":"Hemophilia | Niche and Rare Pharmacor | G7 | 2015"},"content":{"rendered":"<p>Hemophilia is a monogenic bleeding disorder occurring primarily in males. In hemophilia A and hemophilia B, factor VIII or factor IX (respectively) is either absent or deficient in function. Several factor replacement serums are currently approved to treat hemophilia A and B, but a comparatively large unmet need remains for hemophilia A patients because of disappointing factor half-life extensions, compounded by the higher diagnosed prevalence of hemophilia A vs B. Launch of the new longer-acting factor concentrates and agents with novel mechanisms of action, for both type A and B, offer a chance to achieve improvements in clinical outcomes and address compliance issues. Using primary research conducted with expert U.S. and European hemophilia specialists, this report provides a comprehensive analysis of the competitive landscape and market opportunity for hemophilia. It includes a comprehensive analysis of patient populations, current therapies and medical practices, unmet needs, and emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-391200","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematology","biopharma-therapy-areas-hemophilia","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391200\/revisions"}],"predecessor-version":[{"id":394323,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391200\/revisions\/394323"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}